122
Participants
Start Date
February 28, 2011
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
ATH008
The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
Institute Jules Bordet, Brussels
Imelda, Bonheiden
AZ Maria Middelares, St-Niklaas
Complejo Hospitalario Regional Reina Sofia, Córdoba
IRCCS - Istituto Europeo di Oncologia (IEO) di Milano, Milan
Hospital Gregorio Marañón, Madrid
HGU La Paz, Madrid
Hospital Ramón y Cajal, Madrid
"Azienda Ospedaliero Universitaria Maggiore Della Carità di Novara", Novara
Hospital Puerta de Hierro, Majadahonda
Hospital de Navarra, Pamplona
A.O. Universitaria Policlinico S.Orsola-Malpighi di Bologna, Bologna
Institut Valencià d'Oncologia, Valencia
Hospital Miguel Servet, Zaragoza
Iniversitätsklinikum Hamburg Eppendorf, Hamburg
OncoResearch Lerchenfeld UG, Hamburg
Klinikum Offenbach GmbH, Offenbach
Prosper Hospital, Recklinghausen
Azienda Ospedaliero Universitaria di Sassari, Sassari
Institut Català d'Oncología, L'Hospitalet de Llobregat
HGU Alicante, Alicante
Hospital del Mar, Barcelona
Hospital Vall d'Hebron, Barcelona
Hospital General de Elche, Elche
Hospital Clínic i Provincial, Madrid
Hospital de Torrevieja, Torrevieja
Collaborators (1)
Cromsource
INDUSTRY
Advancell - Advanced In Vitro Cell Technologies, S.A.
INDUSTRY